Coronary intravascular lithotripsy for severe coronary artery calcification: The Disrupt CAD I-IV trials

Zachary M. Visinoni, Daniel L. Jurewitz, Dean J. Kereiakes, Richard Shlofmitz, Evan Shlofmitz, Ziad Ali, Jonathan Hill, Michael S. Lee

Research output: Contribution to journalReview articlepeer-review

Abstract

Coronary artery calcification (CAC) severity is associated with increased vessel inflammation, atherosclerosis, stent failure, and risk of percutaneous coronary intervention-related complications. Current modalities for CAC modification include atherectomy techniques (rotational, orbital, and laser) and balloon modification (cutting and scoring). However, these methods are limited by their risk of slow flow/no reflow, coronary dissection, perforation, and myocardial infarction. Intravascular lithotripsy (IVL) emits high-energy sonic waves that induce calcium fractures within a target lesion to improve vessel compliance for stent placement. Low rates of major cardiac adverse events (MACE) and high rates of procedural and angiographic success were observed with IVL in the Disrupt CAD I-IV trials. Optical coherence tomography sub-studies identified calcium fracture as the likely etiology of improved vessel compliance and increased luminal diameter post-IVL. Rates of MACE, procedural, and angiographic success were consistent across the Disrupt CAD trials, suggesting IVL is less operator-dependent compared to other calcium-modifying techniques. Coronary IVL offers interventional cardiologists a safe and effective method of severe CAC modification, while providing reproducible outcomes.

Original languageEnglish
Pages (from-to)81-87
Number of pages7
JournalCardiovascular Revascularization Medicine
Volume65
DOIs
StateAccepted/In press - 2024
Externally publishedYes

Keywords

  • Coronary artery calcification
  • Intravascular lithotripsy
  • Percutaneous coronary intervention

Fingerprint

Dive into the research topics of 'Coronary intravascular lithotripsy for severe coronary artery calcification: The Disrupt CAD I-IV trials'. Together they form a unique fingerprint.

Cite this